Atacand
(Candesartan Cilexetil)ApprovedSmall molecule
Atacand is a small molecule that works as a Type-1 Angiotensin II Receptor Antagonist.[2] It is being used across 12 indications, with its most advanced program in Approved.[1]
Atacand is one of 357 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
12
Indications
39
Total Trials
1
Active Trials
356
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Atacand
IIstituto Clinico Humanitas
Approved
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic
CCephalon
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension7 trials
Efficacy and Safety5 trials
Hypertensive3 trials
Fasting Conditions3 trials
18 more indications
Atorvastatin1 trial
Cardiovascular Events1 trial
COVID-191 trial
Observational Study1 trial
Metabolic Syndrome1 trial
Brain Injury1 trial
Type 2 Diabetes Mellitus1 trial
Interaction1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[4]
Jun 4, 1998
ATACAND
NDA NDA020838
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Candesartan Cilexetil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Type-1 Angiotensin II Receptor Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- IIstituto Clinico Humanitas